May. 11 at 11:55 AM
$ATHE Good Morning from the US! Multiple presentations, two successful Type C meetings with the FDA, multiple publication releases. They are aligning ATHE for either a strategic partnership (with big pharma) or an outright acquisition. They appear to be sowing the seeds towards a strategic relationship (either partnership or acquisition). The mid-2026 meeting with the FDA will be the major catalyst which will determine how Phase 3 trial will be conducted.
